Lataa...
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
BACKGROUND: The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. METHODS: We performed three open-label, dose-escalation phase 1...
Tallennettuna:
| Julkaisussa: | N Engl J Med |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5490784/ https://ncbi.nlm.nih.gov/pubmed/25830326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1502924 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|